Aclaris Therapeutics (ACRS): Raising PT On Additional Ph2 Data - Jefferies

September 19, 2016 8:51 AM EDT
Get Alerts ACRS Hot Sheet
Price: $22.29 +0.77%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 11 | New: 8
Trade ACRS Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies analyst, David Steinberg, reiterated his Buy rating on shares of Aclaris Therapeutis (NASDAQ: ACRS) and raised his price target to $31 from $23. ACRS released additional information on the A-101 common wart Ph2 study last week. Based on the new information, the analyst is increasingly optimistic about the outlook for this second indication for A-101 and thinks the sustainability of this franchise could be further bolstered by new patents.

The analyst increased his peak sales estimate from $75M to $250M and continues to look forward to the important Ph3 data in Q4 for A-101 SK for which he pegs a 75% chance of success.

Flowing the new A-101 warts forecast through the model and assuming incrementally higher SG&A expenses to support a more robust launch, the analyst increased his FY20 & FY21 EPS ests by $0.44 & $1.68 to $2.44 & $4.55.

For an analyst ratings summary and ratings history on Aclaris Therapeutis click here. For more ratings news on Aclaris Therapeutis click here.

Shares of Aclaris Therapeutis closed at $24.50 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment